Quarterly Activities and Cash Flow Report - 30 June 2023

Amplia has released its Quarterly Activities and Cash Flow Report for the quarter ended 30 June 2023.

Key highlights for the period include:

  • Completion of Cohort 2 and currently dosing Cohort 3 in the Phase 1b stage of the ACCENT trial
  • Reported exciting preclinical data showing AMP945 enhances the activity of an alternate treatment for pancreatic cancer called FOLFIRINOX, in a model of the disease
  • Initiated a study with CSIRO to explore topical delivery of our FAK inhibitors for wound healing
  • Announced the name narmafotinib for AMP945

Over the coming quarter, Amplia expects to report further progress in the ACCENT trial as we finalise dose selection for the Phase 2 portion of the trial. 

Preclinical studies with AMP945 in additional indications are also underway to identify further clinical and commercial opportunities for the drug. 

Read today’s ASX release.